J. A. Ware

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

Amy J. Wagner, Johanna C. Bendell, Saoirse Dolly et al. · Journal of Clinical Oncology · 2011 · 72 citations

Tumor Biology, Oral Pi3k/mtor Inhibitor, Human Mtor +15

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors

Andrew J. Wagner, Dayna Hoff, Patricia LoRusso et al. · Journal of Clinical Oncology · 2009 · 64 citations

First-in-human Phase, Nm Ic50, Pharmacotherapy +16

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

Víctor Moreno, Richard D. Baird, Kinjal Shah et al. · Journal of Clinical Oncology · 2011 · 39 citations

Gdc-0941 Plasma Concentrations, Advanced Solid Tumors, Tumor Biology +17

A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941

Debashis Sarker, Rebecca Kristeleit, Kathryn Mazina et al. · Journal of Clinical Oncology · 2009 · 38 citations

Pathology, Gdc-0941 Plasma Concentrations, Pharmacotherapy +17

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

Daniel D. Von Hoff, P. LoRusso, G. D. Demetri et al. · Journal of Clinical Oncology · 2011 · 31 citations

Pathology, Pharmacotherapy, Tumor Biology +17